SurModics expands with Brookwood buy:
This article was originally published in Clinica
Executive Summary
Drug delivery technology provider SurModics has acquired Brookwood Pharmaceuticals, a subsidiary of the Southern Research Institute, for $40m in cash. The deal, which could rise by a further $22m pending the achievement of specific milestones, sees SurModics (Eden Prairie, Minnesota) gain proprietary polymer-based technologies and broaden its range of markets to include oncology, ophthalmology and orthopaedics. Brookwood, which will retain its operating facilities in Birmingham, Alabama, recorded $12.7m in revenues in 2006, and is profitable and cash flow positive, so is expected to be accretive to SurModics' fiscal 2008 earnings.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.